Amgen Inc dividend yield – Investors Take Note: Amgen Set to Pay Upcoming Dividend

🌧️Trending News

Investors may want to take note of Amgen Inc ($NASDAQ:AMGN). as the company is set to pay its upcoming dividend in the near future. Amgen Inc. is also listed on the NASDAQ stock exchange, so investors can buy and sell stock in the company. The company has a track record for reliable dividend payments and their upcoming dividend is sure to benefit those who have invested in the company. Investing in Amgen Inc. can be a great way to diversify an investment portfolio and diversifying by investing in stocks can provide a great source of passive income over time.

Dividends – Amgen Inc dividend yield

Investors who are looking for dividend yields might want to take notice of Amgen Inc. The company has been a consistent dividend payer for the past three years, with a dividend per share of 8.33 USD, 7.76 USD, and 7.04 USD respectively. The dividends yields from 2021 to 2023 are predicted to be 3.29%, 3.26%, and 3.12%, with an average dividend yield of 3.22%.

This is an attractive option for investors who are keen in dividend stocks and are looking for stable returns. As such, Amgen Inc. might be worth considering for investors in the market for dividend stocks.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Amgen Inc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Amgen Inc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Amgen Inc. More…

Key Ratios Snapshot

Some of the financial key ratios for Amgen Inc are shown below. More…

Stock Price

On Monday, AMGEN INC stock opened at $265.7 and closed at $266.7, representing a 0.2% decrease from the previous closing price of $267.3. This upcoming dividend provides a unique opportunity for investors to acquire a portion of the company’s profits in the form of a dividend. Investment experts suggest that investors analyze the stock closely before deciding to purchase shares in the company as this dividend could potentially represent a chance to make a profit, or even just to break even on past investments. Whether or not to take advantage of this dividend offer is ultimately up to the individual investor, but it is worth considering for those interested in making money from their investments in AMGEN INC. Live Quote…

Analysis

GoodWhale conducted an analysis of AMGEN INC‘s financials and the findings show that it is a strong performer in dividend and profitability, and medium in asset. Growth wise, AMGEN INC is weaker. We classified AMGEN INC as a ‘cow’, a type of company that has the track record of paying out consistent and sustainable dividends. This makes AMGEN INC an attractive investment option for dividend-seeking investors and those looking for a hedge against market volatility. Moreover, AMGEN INC has a high health score of 8/10, which is reflective of its strong cashflows and low debt levels. This gives us confidence that AMGEN INC is capable to sustain future operations in times of crisis. These factors make AMGEN INC an appealing investment option for investors who are seeking both dividend income and portfolio diversification. More…

Peers

The competition between Amgen Inc and its competitors is fierce. Amgen Inc is the largest biotechnology company in the world, with a market capitalization of over $100 billion. Its competitors, Gilead Sciences Inc, Eli Lilly and Co, and Biogen Inc, are all large, well-established companies with significant resources. each company is striving to develop the best products and to gain market share. The competition is intense, and each company is working hard to win.

– Gilead Sciences Inc ($NASDAQ:GILD)

Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences Inc has a market cap of 83.2B as of 2022, a Return on Equity of 24.03%. The company’s key products include HIV/AIDS treatment, hepatitis C treatment, and oncology products. Gilead Sciences Inc also has a pipeline of products in development for various indications, including HIV, hepatitis B, non-alcoholic steatohepatitis, and respiratory syncytial virus.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company headquartered in Indianapolis, Indiana. The company was founded in 1876 by Colonel Eli Lilly. The company develops and markets products in the areas of diabetes, oncology, immunology, neuroscience, and other areas. Lilly has operations in more than 60 countries and sells products in more than 125 countries. Lilly has been one of the world’s leading innovators in the pharmaceutical industry, with products such as Prozac, Zyprexa, and Cialis. The company has a market cap of 316.18B as of 2022 and a Return on Equity of 45.88%.

– Biogen Inc ($NASDAQ:BIIB)

Biogen Inc. is a global biotechnology company. The company is engaged in the discovery, development, manufacturing and commercialization of therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune diseases. Biogen has a market cap of $39.12B as of 2022 and a return on equity of 14.98%. The company’s products include aducanumab, a monoclonal antibody for the treatment of Alzheimer’s disease; SPINRAZA, a therapeutic agent for the treatment of spinal muscular atrophy; and TYSABRI, a monoclonal antibody for the treatment of multiple sclerosis.

Summary

AMGEN Inc. is an American multinational biopharmaceutical company that develops and manufactures various drugs and treatments in the areas of cancer, inflammation, and bone health. Investors may be interested in AMGEN Inc. for its upcoming dividend due to its strong financial position and diversified product portfolio. Furthermore, AMGEN Inc. is able to generate consistent cash flow from its core products and international expansion, providing a steady stream of revenue for dividend payments. Additionally, AMGEN’s strong diversification across therapeutic areas reduces exposure to any one product’s success or failure, helping to mitigate risk for investors. Amgen Inc.’s upcoming dividend is a potential opportunity for investors interested in a yield-oriented investment strategy.